Skip to main content

Table 3 Clinical trials of HER2-targeted bispecific antibodies

From: Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

Drug Targets Diseases Treatment arms Phase Status Identifier
Ertumaxomab HER2/CD3 Metastatic breast cancer Ertumaxomab 2 Terminated NCT00452140
Ertumaxomab HER2/CD3 Metastatic breast cancer Ertumaxomab 2 Terminated NCT00522457
Ertumaxomab HER2/CD3 Her2+ advanced solid tumors Ertumaxomab 1/2 Terminated NCT01569412
MM-111 HER2/HER3 Her2+, heregulin+, breast cancer MM-111 1 Completed NCT00911898
MM-111 HER2/HER3 Her2+, heregulin+, breast cancer MM-111 + trastuzumab 1 Completed NCT01097460
MM-111 HER2/HER3 HER2+ solid tumors a. Cisplatin + capecitabin + trastuzumab + MM-111
b. Lapatinib ± trastuzumab + MM-111
c. Paclitaxel + trastuzumab + MM-111
d. Lapatinib + trastuzumab + paclitaxel + MM-111
e. Docetaxel + trastuzumab + MM-111
1 Completed NCT01304784
MM-111 HER2/HER3 HER2+ esophagus cancer, gastroesophageal junction cancer, stomach cancer a. MM-111 + paclitaxel + trastuzumab
b. Paclitaxel + trastuzumab
2 Completed NCT01774851
HER2Bi-aATC HER2/CD3 Her2+ neoplasms of digestive system Interleukin-2 + HER2Bi-aATC 1 Recruiting NCT02662348
MCLA-128 HER2/HER3 HER2+ malignant solid tumors a. MCLA-128 dose escalation
b. MCLA-128 for breast cancer
c. MCLA-128 for ovarian cancer
d. MCLA-128 for gastric/GE junction cancer
e. MCLA-128 for endometrial cancer
f. MCLA-128 for NSCLC
1/2 Recruiting NCT02912949
GBR1302 HER2/CD3 HER2+ solid tumors GBR1302 1 Recruiting NCT02829372
ZW25 Two different epitopes of HER2 HER2+ solid tumors ZW25 1 Recruiting NCT02892123
  1. The details of Table 3 derived from http://clinicaltrials.gov/